Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.
Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, King C, Griffin S, Ramachandran R, Odler B, Eller K, Artan AS, Mirioglu S, Busch M, Schaepe M, Turkmen K, Cheung CK, Pepper RJ, Juarez GF, Pascual J, Auñón P, García-Carro C, Rodriguez A, Alberici F, Luzardo L, Chebotareva N, Schönermarck U, Fernández L, Radhakrishnan J, Guaman K, Peleg Y, Hoisnard L, Audard V, Papasotiriou M, Krnanska N, Tesar V, Hruskova Z, Bruchfeld A, Stangou M, Lioulios G, Faguer S, Ribes D, Salhi S, Windpessl M, Galešić K, Crnogorac M, Zagorec N, Mayer G, Kronbichler A; RITERM Study Team.
Gauckler P, et al. Among authors: windpessl m.
J Am Soc Nephrol. 2024 Oct 16. doi: 10.1681/ASN.0000000520. Online ahead of print.
J Am Soc Nephrol. 2024.
PMID: 39431468